Head-to-head evidence
dapiglutide vs ZT006
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
dapiglutide
Developed by Zealand Pharma
NCT06758583 · Phase 1 · completed
Both groups received active dapiglutide at different concentrations with no placebo or blinding, and the study measured only drug levels in the blood rather than a clinical effect. No results have been posted.
ZT006
Developed by Beijing QL Biopharmaceutical
NCT07307638 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled trial, but its primary endpoints are adverse-event rates rather than a weight-loss outcome, and no results have been posted yet, so its effect on body weight is unknown.
Next expected readout: December 2026 · NCT07230132 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dapiglutide's landscape · ZT006's landscape